• +1-646-491-9876
    • +91-20-67278686

    Search

    Insulin Resistance Pipeline Review H2 2017

    Insulin Resistance Pipeline Review H2 2017

    • Report Code ID: RW0001884139
    • Category Pharmaceuticals
    • No. of Pages 44
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Insulin Resistance - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H2 2017, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

    Insulin resistance (IR) is a condition in which the body's cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the body's own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

    Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Insulin Resistance - Overview
    Insulin Resistance - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Insulin Resistance - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Insulin Resistance - Companies Involved in Therapeutics Development
    Amgen Inc
    AusBio Ltd
    F. Hoffmann-La Roche Ltd
    GlaxoSmithKline Plc
    Hadasit Medical Research Services & Development Ltd
    Pfizer Inc
    Prometheon Pharma LLC
    Sanofi
    Insulin Resistance - Drug Profiles
    ATA-842 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    englerin A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FC-98 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    L-2286 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MD-960 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MD-961 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Agonize Oxytocin Receptor for Obesity and Insulin Resistance - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-7992 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAR-088 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sildenafil citrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Target AGTR1 and PPAR Gamma for Hypertension and Insulin Resistance - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit TRIP-Br2 for Obesity and Insulin Resistance - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SYM-401 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TM-25659 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Insulin Resistance - Dormant Projects
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Insulin Resistance, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Insulin Resistance - Pipeline by Amgen Inc, H2 2017
    Insulin Resistance - Pipeline by AusBio Ltd, H2 2017
    Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
    Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H2 2017
    Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2017
    Insulin Resistance - Pipeline by Pfizer Inc, H2 2017
    Insulin Resistance - Pipeline by Prometheon Pharma LLC, H2 2017
    Insulin Resistance - Pipeline by Sanofi, H2 2017
    Insulin Resistance - Dormant Projects, H2 2017

    List of Figures

    Number of Products under Development for Insulin Resistance, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Amgen Inc
    AusBio Ltd
    F. Hoffmann-La Roche Ltd
    GlaxoSmithKline Plc
    Hadasit Medical Research Services & Development Ltd
    Pfizer Inc
    Prometheon Pharma LLC
    Sanofi

    Request for Sample

    Report Url http://www.reportsweb.com//insulin-resistance-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//insulin-resistance-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//insulin-resistance-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments